Core Viewpoint - Xiamen Securities Regulatory Bureau issued a warning letter to Huafu Securities for failing to perform due diligence in its role as the sponsor for Jiangping Biological's private placements, leading to undisclosed false information in the company's financial documents [1][3]. Group 1: Regulatory Actions - Huafu Securities was found to have not adequately verified Jiangping Biological's information disclosure and private placement application documents during two fundraising rounds in 2021 and 2022 [2][3]. - The warning letter will be recorded in Huafu Securities' integrity file as part of the regulatory measures taken by the Xiamen Securities Regulatory Bureau [3]. Group 2: Financial Misconduct - Jiangping Biological inflated its reported revenue by CNY 147 million and CNY 152 million for the years 2021 and 2022, respectively, which accounted for 68.62% and 64.87% of the company's disclosed revenues for those years [3]. - The company also inflated its total profit by CNY 589.4 million and CNY 569.1 million for 2021 and 2022, representing 130.43% and 119.77% of the reported total profits for those years [3]. Group 3: Penalties Imposed - The Xiamen Securities Regulatory Bureau imposed a total fine of CNY 12.6 million on Jiangping Biological's former executives, including the chairman, general manager, and other key personnel, for their involvement in the financial misconduct [3].

《意见》共23条，涉及总体要求、投资者保护、市场参与人规范、司法行政协同及组织实施保障等方 面，旨在严格公正执法司法，保障资本市场改革发展。 高质量信息披露是注册制的重要基础。为让投资者放心投资，《意见》明确，监管部门要进一步加大对 欺诈发行和持续信息披露造假的日常监管与稽查处罚力度，从严从快查处各类造假行为，强化与司法机 关在信息共享、案件办理等方面的协作，推动强化行政、民事、刑事立体追责。 对于引领净化资本市场生态，《意见》提出，依法打击编传虚假信息、"维权黑产"、发行上市环节不正 当竞争等干扰市场正常运行、扰乱资本市场秩序的违法行为，形成风清气正的市场生态。对于通过编 传"小作文"等虚假信息扰乱市场秩序、损害他人权益的行为，受害人提起民事诉讼要求损害赔偿的，人 民法院依法予以支持；构成犯罪的，依法追究刑事责任。 《意见》还称，研究制定资本市场法律域外适用司法文件，为审理跨境证券期货纠纷案件统一裁判尺 度，平等保护境内外投资者合法权益。 15日，中国最高人民法院、证监会联合发布《关于严格公正执法司法服务保障资本市场高质量发展的指 导意见》(下称《意见》)。 其中明确，聚焦投资者权益保护，优化市场生态。《意 ...